UBS, alongside PWC, played a pivotal role in advising on the recent acquisition of Mallinckrodt’s Therakos business by CVC Capital Partners, a deal valued at $925 million.
This strategic move is part of Mallinckrodt’s broader initiative to streamline its operations and focus on its core competencies in specialty pharmaceuticals.
Therakos is renowned for its
Already a member? Log in here
You must be logged in to post a comment.